TELEFLEX INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 206.5 USD | -3.07% |
|
-5.50% | -17.17% |
Financials (USD)
| Sales 2024 * | 3.09B | Sales 2025 * | 3.26B | Capitalization | 9.73B |
|---|---|---|---|---|---|
| Net income 2024 * | 409M | Net income 2025 * | 543M | EV / Sales 2024 * | 3.49 x |
| Net Debt 2024 * | 1.06B | Net Debt 2025 * | 507M | EV / Sales 2025 * | 3.14 x |
| P/E ratio 2024 * |
26.6
x | P/E ratio 2025 * |
18.3
x | Employees | 14,500 |
| Yield 2024 * |
0.66% | Yield 2025 * |
0.67% | Free-Float | 97.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Teleflex Incorporated
More recommendations
More press releases
More news
| 1 day | -3.07% | ||
| 1 week | -5.50% | ||
| Current month | -1.06% | ||
| 1 month | -2.16% | ||
| 3 months | -13.13% | ||
| 6 months | -5.35% | ||
| Current year | -17.17% |
1 week
205.83
217.43
1 month
197.99220.27
Current year
197.99256.85
1 year
177.63262.97
3 years
177.63428.36
5 years
177.63449.38
10 years
101.95449.38
| Managers | Title | Age | Since |
|---|---|---|---|
Liam Kelly
CEO | Chief Executive Officer | 57 | 08-12-31 |
Thomas Powell
DFI | Director of Finance/CFO | 62 | 11-07-31 |
Howard Cyr
CMP | Compliance Officer | - | 17-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrew Krakauer
BRD | Director/Board Member | 69 | 17-12-31 |
Stuart Randle
BRD | Director/Board Member | 64 | 08-12-31 |
John Heinmiller
BRD | Director/Board Member | 69 | 18-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.03% | 14 M€ | -3.15% | ||
| 0.73% | 8 M€ | 0.00% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 206.5 | -3.07% | 1,042,787 |
| 24-05-22 | 213.1 | +0.05% | 283,091 |
| 24-05-21 | 213 | -0.75% | 637,044 |
| 24-05-20 | 214.6 | -1.40% | 527,455 |
| 24-05-17 | 217.6 | -0.43% | 392,913 |
Delayed Quote Nyse, May 23, 2024 at 04:00 pm EDT
More quotes
Teleflex Incorporated specialises in the designing, manufacturing and selling of single-use medical devices for hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. Products are sold under the brand names Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck®. Net sales break down by category of products as follows:
- interventional cardiology, radiology and urology products (26.5%);
- vascular access solutions (25.9%);
- surgical devices (12.5%);
- anesthesia products (11.9%);
- other (23.2%).
Net sales are distributed geographically as follows: the United States (61.8%), Europe (25.5%), Asia-Pacific (9.1%) and other (3.6%).
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
206.5
USD
Average target price
245.2
USD
Spread / Average Target
+18.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.17% | 10.04B | |
| -5.31% | 182B | |
| -1.21% | 114B | |
| -5.53% | 67.76B | |
| +1.22% | 51.91B | |
| +7.03% | 43.23B | |
| +5.53% | 41.07B | |
| +21.96% | 32.07B | |
| +13.80% | 25B | |
| -4.81% | 24.55B |
- Stock Market
- Equities
- TFX Stock
